Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.75 (1.66%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £42.17m
TIME Live PriceLast checked at - London Stock Exchange

Intraday Time Finance Share Chart

Q3 Trading Update

26 Mar 2024 07:00

RNS Number : 2229I
Time Finance PLC
26 March 2024
 

26 March 2024

Time Finance plc

("Time Finance", the "Group" or the "Company")

 

Q3 Trading Update

Eleventh consecutive quarter of loan book growth

40% increase in 9 month Profit over corresponding period; already in excess of FY 2022/23 total

 

Time Finance plc, the AIM listed independent specialist finance provider, is pleased to provide the following trading update for the nine-month period ended 29 February 2024. The Group's robust performance in the first half has been maintained throughout the third quarter of the current financial year. Continued strong demand from UK businesses for the Group's multi-product offering is driving further growth in own-book lending origination which has contributed to a record gross lending book of more than £190m at the end of February 2024. This is the eleventh consecutive quarter of loan book growth for the Company.

 

Unaudited 9 month 2023/24 financial highlights:

 

· Own-Book lending origination up 25% to £66.0m (9M 2022/23: £52.9m)

· Revenue up 20% to £24.0m (9M 2022/23: £20.0m)

· Profit Before Tax ("PBT") up 40% to £4.2m (9M 2022/23: £3.0m)

· Strong visibility of future earnings with unearned income up 27% to £24.6m at 29 February 2024 (28 February 2023: £19.4m)

· Gross lending-book up 21% to £190.3m at 29 February 2024 (28 February 2023: £157.2m)

· Net Arrears unchanged at 6% of the gross lending book at 29 February 2024 (28 February 2023: 6%)

· Net Tangible Assets up 14% to £37.6m (28 February 2023: £33.0m)

 

Revenue continues to be driven by strong growth in the larger-ticket, more secured lending areas of Invoice Finance and the 'Hard Asset' subset of Asset Finance.

 

Ed Rimmer, Chief Executive Officer commented:

 

"These results demonstrate that the Group's multi-product range combined with its focus on customer service continue to resonate with UK businesses. Despite the well-publicised, wider macro-economic 'headwinds', the Group has produced another strong trading performance in Q3 whilst, crucially, maintaining its strict focus on credit risk and spread. I am particularly pleased that the profit generated in the first nine months of the current financial year has already surpassed the level achieved for the whole of the previous year. Such continuing positive trading momentum gives the Board confidence that full-year trading will be at least in line with the market expectations as upgraded on 5 March 2024.

 

The Group remains extremely well positioned to deliver further growth and I look forward to reporting on yet more progress at our financial year-end and on delivering increased value for all of our shareholders."

 

The Group will provide an update on trading for the full year to 31 May 2024 in late June 2024.

 

 

 

 

For further information, please contact:

 

Time Finance plc 01225 474230

Ed Rimmer, Chief Executive Officer

James Roberts, Chief Financial Officer

 

Cavendish Capital Markets (Nominated Advisor and Broker) 0207 220 0500

Ben Jeynes / Dan Hodkinson (Corporate Finance)

Michael Johnson / George Budd / Charlie Combe (Sales and ECM)

 

Walbrook PR 0207 933 8780

Nick Rome/Joe Walker timefinance@walbrookpr.com

 

 

About Time Finance:

Time Finance's purpose is to Help UK Businesses Thrive and Survive through the provision of flexible funding facilities. It offers a multi-product range for SMEs concentrating on Asset, Loan and Invoice Finance. While focussed on being an 'own-book' lender, the Group does retain the ability to broke-on deals where appropriate, enabling it to optimize business levels through market and economic cycles.

 

More information is available on the Company website www.timefinance.com.

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFDVSIEFIS
Date   Source Headline
21st Sep 20217:00 amRNS2021 Final Results
7th Sep 20217:00 amRNSNotice of Final Results and Investor Presentation
16th Jun 20217:00 amRNSYear-end Trading Update
10th Jun 20217:00 amRNSPermanent CEO Appointment & Investor Presentation
4th Jun 202111:30 amRNSHolding(s) in Company
4th Jun 202111:25 amRNSHolding(s) in Company
27th May 20215:29 pmRNSEmployee Benefit Trust Share Purchase
27th May 20217:00 amRNSExercise of Options
21st May 20217:00 amRNSUnapproved Share Option Scheme – Vesting of Awards
6th May 20217:00 amRNSNew Loan Accreditation & Financial Calendar Update
22nd Apr 20217:00 amRNSCorporate Update
9th Apr 20212:58 pmRNSEmployee Benefit Trust Share Purchase
26th Mar 20217:00 amRNSDirectorate Change
3rd Mar 20217:00 amRNSFurther re Directorate Change
19th Feb 202112:04 pmRNSDirectorate Changes
3rd Feb 20217:00 amRNSTechnology Infrastructure Update
19th Jan 20217:00 amRNSInterim Results
12th Jan 20217:00 amRNSHolding in Company
12th Jan 20217:00 amRNSHolding in Company
6th Jan 20217:00 amRNSDirectorate Changes
15th Dec 20205:15 pmRNSTR-1: Holding in Company - CORRECTION
9th Dec 20207:00 amRNSHalf Year Trading Update & Investor Presentation
1st Jun 20103:19 pmRNSResult of EGM
28th May 20107:00 amRNSUpdate
6th May 20108:37 amRNSStrategic Review - update
6th May 20107:01 amRNSNotice of EGM
6th May 20107:00 amRNSAppointment of adviser
4th May 201011:22 amRNSForm 8.3 - Timestrip PLC
4th May 20107:00 amRNSForm 8 (OPD) Timestrip
19th Apr 20107:30 amRNSStrategic Review Update and Suspension
19th Apr 20107:30 amRNSSuspension - Timestrip plc
24th Mar 20109:50 amRNSRule 8.1- (Timestrip)
19th Mar 201012:47 pmRNSStrategic Review - Update
18th Mar 20107:00 amRNSStrategic Review
5th Feb 20109:04 amRNSDirectorate Change
3rd Feb 20104:29 pmRNSAIM Rule 17
1st Feb 20107:00 amRNSContract Win - Toothbrush Order
5th Nov 200912:23 pmRNSUK Packaging Awards
28th Oct 20097:00 amRNSTimestrip IV - First full adoption by NHS Trust
26th Oct 20097:00 amRNSTimestrip Medical - 1st order in North America
14th Sep 20097:01 amRNSHalf Yearly Report
14th Sep 20097:00 amRNSNHS trials and appointment of distributor
24th Jul 20092:18 pmRNSResult of AGM
6th Jul 20097:00 amRNSNew distribution agreement
1st Jul 20097:00 amRNSPreliminary findings on Timestrip IV
29th Jun 20091:26 pmRNSNotice of AGM
11th Jun 20097:00 amRNSFinal Results
8th May 20097:00 amRNSIssue of Equity
5th May 20097:00 amRNSLuton & Dunstable Hospital orders TimestripIV
28th Apr 20097:00 amRNSTimestripIV showcased in NHS funded project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.